BIOGEN INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 190.5 USD | -0.85% |
|
-6.46% | -26.37% |
| Apr. 17 | UBS Adjusts Biogen's Price Target to $214 From $250, Maintains Neutral Rating | MT |
| Apr. 17 | Wedbush Cuts Biogen's Price Target to $213 From $245 | MT |
Financials (USD)
| Sales 2024 * | 9.46B | Sales 2025 * | 9.54B | Capitalization | 27.93B |
|---|---|---|---|---|---|
| Net income 2024 * | 1.89B | Net income 2025 * | 2.2B | EV / Sales 2024 * | 3.24 x |
| Net Debt 2024 * | 2.7B | Net Debt 2025 * | 289M | EV / Sales 2025 * | 2.96 x |
| P/E ratio 2024 * |
14.6
x | P/E ratio 2025 * |
12.6
x | Employees | 7,570 |
| Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 85.34% |
More Fundamentals
* Assessed data
More news
Latest transcript on Biogen Inc.
More recommendations
More press releases
| 1 day | -0.85% | ||
| 1 week | -6.46% | ||
| Current month | -11.64% | ||
| 1 month | -13.16% | ||
| 3 months | -22.86% | ||
| 6 months | -27.70% | ||
| Current year | -26.37% |
1 week
189.52
199.53
1 month
189.52221.74
Current year
189.52268.30
1 year
189.52319.76
3 years
187.16468.55
5 years
187.16468.55
10 years
187.16480.18
| Managers | Title | Age | Since |
|---|---|---|---|
| Chief Executive Officer | 64 | 22-11-13 | |
| Director of Finance/CFO | 60 | 20-08-14 | |
Nicole Murphy
COO | Chief Operating Officer | - | 14-12-31 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Stephen Sherwin
BRD | Director/Board Member | 75 | 09-12-31 |
William Hawkins
BRD | Director/Board Member | 70 | 19-06-18 |
Caroline Dorsa
CHM | Chairman | 64 | 10-01-02 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 4.30% | 1 M€ | 0.00% | - | |
| 3.92% | 0 M€ | 0.00% | - | |
| 3.75% | 0 M€ | 0.00% | - | |
| 2.39% | 14,021 M€ | +2.68% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-04-18 | 190.5 | -0.85% | 1,502,032 |
| 24-04-17 | 192.2 | -1.53% | 1,320,707 |
| 24-04-16 | 195.2 | -0.84% | 872,004 |
| 24-04-15 | 196.8 | -0.70% | 1,159,247 |
| 24-04-12 | 198.2 | -2.70% | 1,245,896 |
Delayed Quote Nasdaq, April 18, 2024 at 04:00 pm EDT
More quotes
Biogen Inc. is one of the world's leaders in the design, manufacturing, and marketing of therapeutic products. Net sales break down by source of income as follows:
- sales of medicines (73,7%): for treating multiple sclerosis, chronic psoriasis in adults, rheumatoid arthritis, cancers, etc.;
- royalties (17,2%) ;
- other (9,1%): primarily revenues from partnership agreements.
Sector
Pharmaceuticals
Calendar
2024-04-23
- Q1 2024 Earnings Release
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
34
Last Close Price
192.2
USD
Average target price
292.6
USD
Spread / Average Target
+52.26%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -26.37% | 27.93B | |
| -5.32% | 84.57B | |
| +3.95% | 39.93B | |
| +52.09% | 24.21B | |
| -6.59% | 17.17B | |
| -32.37% | 13.93B | |
| -10.45% | 12.3B | |
| -15.88% | 11.84B | |
| -2.85% | 7.91B | |
| +0.53% | 7.48B |
- Stock Market
- Equities
- BIIB Stock
